IRODALOM:
1. Yantiss RK,. Odze RD: Optimal Approach to Obtaining Mucosal Biopsies for Assessment of Inflammatory Disorders of the Gastrointestinal Tract. Am J Gastroenterol 2009;104:774-83.
2. Tahara T., Shibata T., Nakamura M., Yoshioka D., Okubo M., Arisawa T., Hirata I: Gastric mucosal pattern by using magnifying narrow-band imaging endoscopy clearly distinguishes histological and serological severity of chronic gastritis. Gastrointest Endosc 2009;70:246-53.
3. Adamopoulos AB, Stergiou GS, Sakizlis GN, Tiniakos DG, Nasothimiou EG, Sioutis D.K. és mtsai:
Diagnostic value of rapid urease test and urea breath test for Helicobacter pylori detection in patients with Billroth II gastrectomy: a prospective controlled trial. Dig Liver Dis 2009;41:4-8.
4. de Vries AC, Haringsma J, de Vries RA, Borg F, Nagtzaam NM, Steyerberg EW és mtsai: The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. Gastrointest Endosc 2009;70:18-25.
5. Cover LT, Blaser MJ: Helicobacter pylori in health and disease Gastroenterology 2009;136:1863-73.
6. Graham DY: Efficient identification and evaluation of effective Helicobacter pylori therapies Clin
Gastroenterol Hepatol 2009;7:145-8.
7. Weyerman M, Rothenbacher D, Brenner H: Acqusition of Helicobacter pylori infection in early childhood: Independent contributions of infected mothers, fathers, and siblings Am J Gastroenterol 2009;104:182-9.
8. Fukase K, Kato M, Kikuchi S és mtsai: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. Lancet 2008:372:392-7.
9. de Vries AC., Kuipers EJ., Rauws EAJ.: Helicobacter pylori eradication and gastric cancer: When is the horse out of the barn? Am J Gastroenterol 2009;104:1342-5.
10. Wu CY, Kuo MS, Chen YJ és mtsai: Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with paptic ulcer disease. Gastroenterology 2009;137:1641-8.
11. Robertson DJ, Sandler RS, Ahnen DJ és mtsai: Gastrin, Helicobacter pylori, and colorectal adenomas Clin Gastroenterol Hepatol 2009;7:163-7.
12. Jafri NS, Hornung CA, Howden VW: Metanalysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patient with naive to treatment Ann Intern Med 2008; 148:923-31.
13. Luther JH PYLORI, Schoenfeld P, Moayyedi P és mtsai: Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systemic review and meta-analysis of efficacy and tolerability Am. J. Gastroenterol 2010;105:65-73.
14. Moayyedi P, Malfertheiner P: Editorial: Sequential therapy for eradication of Helicobacter pylori: A new guiding light or a false dawn? Am J Gastroenterol 2009;104:3081-3.
15. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D: Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. American Journal of Gastroenterology. 2009;104(1):21-5.
16. Vakil N: H. pylori treatment: New wine in old bottles? Am J Gastroenterol 2009; 104:26-30.
17. Wang C, Yuan Y, Hunt RH: Helicobacter pylori infection and Barrett’s esophagus: a systemic review and
meta-analysis Amer J Gastroenterol 2009;104:492-500.
18. Marrelli D, Pedrazzani C, Berardi A és mtsai: Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer. Cancer. 2009 May 15;115(10):2071-80.
A gyomor 131
19. Reimer C, Sondergaard B, Hilsted L, Bytzer P: Proton-pump inhibitor therapy induces acid-related symptomes in healthy volunteers after withdrawal of therapy Gastroenterology 2009;137:80-87.
20. McColl KEL és Gillen D: Evidence that protom-pump inhibitor therapy induces the symptoms it is used to treat Gastroenterology 2009;137:20-22.
21. McColl KEL: How I manage H. pylori-negative, NSAID/Aspirin- negative peptic ulcer Am J Gastroenterol 2009;104:190-2.
22. Wong GLH, Wong vWs, Chan Y és mtsai: High incidence of mortality and recurrant bleeding in patients with Helicobacter pylori-negatíve idiopathic bleeding ulcers Gastroenterology 2009;137:525-31.
23. Aro P, Talley NJ, Ronkainen J és mtsai: Anxiety is associated with uninvestigated and functional dyspepsia (Rome III criteria) in a Swedish population-based study Gastroenterology 2009;137:94-100.
24. Van Oudenhove L és Tack J: New epidemiologic evidence an functional dyspepsia subgroups and their relationship to psychological dysfunction Gastroenterology 2009;137:23-26.
25. Laine L, Hennekens C: Proton pump inhibitor and clopidogrel interaction: Fact or fiction? Am J. Gastroenterol 2010;105:34-41.
26. Simon T, Verstuyft C, Mary-Krause M és mtsai.: Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 2009;360:363-75.
27. O’Donoghue ML, Braunwald E, Antman EM és mtsai: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel wirh and without a porton-pump inhibitor: an analysis of two randomized trials Lancet 2009;374:989-97.
28. Bajaj JS, Zadvornova Y, Heuman DM: Association of proton pump inhibition therapy with spontaneous bacterial peritonitis in cirrhotic patients wirh ascites. Am J Gastroenterol 2009;104:1130-4.
29. McColl KEL: Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009;104:S5-9.
30. Dial S: Proton pump inhibitor use and enteric infections Am J Gastroenterol 2009;104:S10-16.
31. Vakil N: Acid inhibition and infections outside the gastrointestinal tract. Am J Gastroenterol 2009; 104:S17-20.
32. Insogna KL: The effect of proton pump-inhibiting drugs on mineral metabolism Am J Gastroenterol 2009;104:S2-4.
33. Laine L: Proton Pump inhibitors and bone fractures? Am J Gastroenterol 2009;104:S21-6.
34. Heidelbaugh JJ, Goldberg KL, Inodami JM: Overutilisation of proton pump inhibitors: a review of
cost-effectiveness and risk in PPI Am J Gastroenterol 2009;104:S27-32.
35. Everhart JE: Burden of digestive diseases in United States Part I:Overall and upper gastrointestinal diseases Gastroenterology 2009;136:376-86.
36. Fass R: Proton pump inhibiton failure – What are the therapeutic options? Am J Gastroenterol 2009; 104:S33-38.
37. Yang HB, Sheu BS, Wang ST és mtsai: H.pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole Am J Gastroenterol 2009; 104:1642-9.
38. Gill SK, O’Brien L, Einarson TR és mtsai: The safety of proton pump inhibitors (PPIs) in pregnancy: A meta-analysis Am J Gastroenterol 2009;104:1541-5.
39. Malfertheiner P, Chan FKL., McColl KEL: Peptic ulcer disease Lancet 2009;374:1449-62.
40. Van Boxel, Hagenaars MP, Smout AJPM, Siersema PD: Sociodempgraphic factors influence use of proton pump inhibitors among users of non-steroidal anti-inflammatory drugs Clin Gastroenterol Hepatol 2009;7:855-61.
132 Gastro Update 2010
41. Laine L, McQuaid KR: Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials Clin Gastroenterol Hepatol 2009;7:33-47.
42. ASGE Technology Committee: Endoscopic hemostatic devices. Gastrointest Endosc 2009;69:987-96.
43. Chiu PW, Ng EK, Cheung FK, Chan FK, Leung WK, Wu JC és mtsai: Predicting mortality in patients
with bleeding peptic ulcers after therapeutic endoscopy. Clin Gastroenterol Hepatol 2009;7:311-16.
44. Loffroy R, Guiu B, D’Athis P, Mezzetta L, Gagnaire A, Jouve JL és mtsai: Arterial embolotherapy for endoscopically unmanageable acute gastroduodenal hemorrhage: predictors of early rebleeding. Clin Gastroenterol Hepatol. 2009;7:515-23.
45. Wong RC: Nonvariceal upper gastrointestinal hemorrhage: probing beneath the surface. Gastroenterology 2009;137:1897-1911.
46. Shaheen AA, Kaplan GG, Myers RP: Weekend versus weekday admission and mortality from gastrointestinal hemorrhage caused by peptic ulcer disease. Clin Gastroenterol Hepatol 2009;7:303-10.
47. Cooper GS, Kou TD, Wong RCK: Outpatient management of nonvariceal upper gastrointestinal haemorrhage: unexpected mortality in medicare beneficiaries Gastroenterology 2009;136:108-114.
48. Müller T, Barkun AN, Martel M és mtsai: Non-variceal upper GI bleeding in patients already hospitelized for another condition Am J Gastroenterol 2009;104:330-9.
49. Ananthakrishnan AN, Mcginley EL, Saeina K: Outcomes of weekend admission for upper gastrointestinal hemorrhage: a nationalwide analysis. Clin Gastroenterol hepatol 2009;7:296-302.
50. Sung J, Tsoi K, Men-Yee Y és mtsai: Causes of mortality in patients with peptic ulcer bleeding: a cohort study of 10428 Amer J. Gastroenterol 2010;105:84-9.
51. Lanas A, Garcia-Rodríguez LA, Polo-Thomas M és mtsai: Time trend and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice Am. J. Gastroenterol 2009;104:1633-41.
52. Targownik LE, Bolton JM, Metge CJ: Selective serotonin reuptake inhibitors are associated with a modest increase in risk of upper gastrointestinal bleeding Amer J Gastroenterol 2009;104:1475-82.
53. Dall M, Schaffalitzky de Muckadell OB, Touborg Lassen A és mtsai: An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding Clin Gastroenterol Hepatol 2009;7:1314-21.
54. Burris JM, Lin PH, Johnston WF és mtsai: Emergent embolization of the gastroduodenal artery in the treatment of upper gastrointestinal bleeding. The experience from a surgeon-initiated interventional program Am J Surg. 2009 Jul;198(1):59-63.
55. Kang J-H, JS Lim, J-H Kim, WJ Hyung, YE Chung, J-Y Choi, M-S Park, M-J Kim és K.Wh Kim: Role of EUS and MDCT in the diagnosis of gastric submucosal tumors according to the revised pathologic concept of gastrointestinal stromal tumors. Eur Radiol (2009) 19: 924-934.
56. Park MJ, WJ Lee, HK Lim, KW Park, JY Choi and B-T Kim: Detecting recurrence of gastric cancer: the value of FDG PET/CT. Abdom Imaging (2009) 34:441-447.
57. Chen Ch-Y, Y-T Kuo, Ch-H Lee, T-J Hsieh, Ch-M Jan, T-Sh Jaw, W-T Huang, F-J Yu: Differentiation between malignant and benign gastric ulcers: CT virtual gastroscopy versus optical gastroendoscopy. Radiology 2009;252:410-4171.
58. Cronin CG, G Dowd, J Ni Mhuircheartaigh, E DeLappe, RH Allen, C Roche, JM Murphy: Hypotonic MR duodenography with water ingestion alone: feasibility and technique. Eur Radiol (2009) 19: 1731-1735.
59. Dinis-Ribeiro M, Pimentel-Nunes P, Afonso M, Costa N, Lopes C, Luis Moreira-Dias L: A European case series of endoscopic submucosal dissection for gastric superficial lesions. Gastrointest Endosc 2009;69:350-55.
A gyomor 133
60. Goto O, Fujishiro M, Kodashima S, Ono S, Niimi K, Hirano K és mtsai: A second-look endoscopy after endoscopic submucosal dissection for gastric epithelial neoplasm may be unnecessary: a retrospective analysis of postendoscopic submucosal dissection bleeding. Gastrointest Endosc 2009 nov 16. [Epub ahead of print].
61. Hoteya S, Iizuka T, Kikuchi D, Yahagi N: Benefits of endoscopic submucosal dissection according to size and location of gastric neoplasm, compared with conventional mucosal resection. J Gastroenterol Hepatol 2009;24:1102-06.
62. Farrell JJ: “Adjuvant” therapy after endoscopic mucosal resection of early gastric cancer. Gastroenterology 2009;137:377-79.
63. Yamashita H: Chromoendoscopy with indigo carmine dye added to acetic acid in the diagnosis of gastric neoplasia. Gastrointest Endosc 2009;69:1407-08.
64. Vakil N, Talley N, van Zanten SV, Flook N, Persson T, Björck E és mtsai: Cost of Detecting Malignant Lesions by Endoscopy in 2741 Primary Care Dyspeptic Patients Without Alarm Symptoms. Clin Gastroenterol Hepatol. 2009;7:756-61.
65. Lee CK, Chung IK, Lee SH, Lee SH, Lee TH, Park SH és mtsai: Endoscopic partial resection with the unroofing technique for reliable tissue diagnosis of upper GI subepithelial tumorsoriginating from the muscularis propria on EUS. Gastrointest Endosc. 2009 Oct 29. [Epub ahead of print]
66. Kim JH, Lee YC, Kim H, Song KH, Lee SK, Cheon JH és mtsai: Endoscopic resection for undifferentiated early gastric cancer. Gastrointest Endosc 2009;69:e1-e9.
67. Mouri R, Yoshida S, Tanaka S, Oka S, Yoshihara M, Chayama K: Evaluation and validation of computed virtual chromoendoscopy in early gastric cancer. Gastrointest Endosc 2009;69:1052-8.
68. Probst A, Golger D, Arnholdt H, Messmann H: Endoscopic Submucosal Dissection of Early Cancers, Flat Adenomas, and Submucosal Tumors in the Gastrointestinal Tract. Clin Gastroenterol Hepatol. 2009;7:149-55.
69. Lee TH, Chung IK, Park JY, Lee CK, Lee SH, Kim HS és mtsai: Usefulness of magnifying endoscopy in post-ER scar for early gastric neoplasm: A prospective short-term follow-up endoscopy study. World J Gastroenterol 2009;15: 349-55.
70. Yao K, Anagnostopoulos GK, Ragunath K: Magnifying endoscopy for diagnosing and delineating early gastric cancer. Endoscopy 2009; 41:462-67.
71. Yokoyama A, Inoue H, Minami H, Ikeda H, Wada Y, Hama S, Novel és mtsai: Magnifying Endoscopic Classification for Early Gastric Cancer with Narrow Band Imaging System; Particularly Focusing On Micro-Vascular Pattern and Surface Glandular Structure. Gastrointest Endosc 2009;69:AB365.
72. Kato M, Kaise M, Yonezawa J, Goda K, Toyoizumi H, Yoshimura N, Yoshida Y, Kawamura M és mtsai:
Trimodal imaging endoscopy may improve diagnostic accuracy of early gastric neoplasia: a feasibility study Gastrointest Endosc. 2009;70:899-906.
73. Nonaka K, Arai S, Ban S, Nagata K, Nakao M, Nakai Y és mtsai: Differential Diagnosis Between Adenoma and Carcinoma for the Gastric Superficial Elevated Lesions By Using Magnified Endoscopy Combined with Narrow-Band Imaging. Gastrointest Endosc 2009;69:AB185.
74. Toyoizumi H, Kaise M, Arakawa H, Yonezawa J, Yoshida Y, Kato M és mtsai: Ultrathin endoscopy versus high-resolution endoscopy for diagnosing superficial gastric neoplasia. Gastrointest Endosc 2009; 70:240-45.
75. Cahill RA, Asakuma M, Perretta S, Leroy J, Dallemagne B, Marescaux J, Coumaros D: Supplementation of endoscopic submucosal dissection with sentinel node biopsy performed by natural orifice transluminal endoscopic surgery (NOTES). Gastrointest Endosc 2009;69(6):1152-60.
76. Hartgrink HH, Jansen EPM, van Grinken NCT és mtsai: Gastric cancer Lancet 2009;374 477-91.
134 Gastro Update 2010
77. Murphy G, Pfeiffer R, Camargo M és mtsai: Meta-analysis shows that prevalence of Epstein-Barr viruse-positive gastric cancer differs based on sex and anatomic location Gastroenterology 2009; 137:824-33.
78. Carmack SW, Genta RM, Schuler CM és mtsa: The current spectrum of gastric polyps: A 1-year national study of over 120000 patients Am J Gastroenterol 2009;104:1524-32.
79. Genta RM, Schuller CM, Robiou CT, Lash RH: No association between gastric fundic gland polyps and gastrointestinal neoplasia in study of over 100000 patients Clin Gastroenterol Hepatol 2009;7:849-54.
80. Genta RM, Schuller CM, Robiou CT, Lash RH: No association between gastric fundic gland polyps and gastrointestinal neoplasia in study of over 100000 patients Clin Gastroenterol Hepatol 2009;7:849-54.
81. Ren JS, Kamangar F, Qiao YL és mtsai: Serum pepsinogens and risk of gastric and oesophagus cancers in the General Population Nutrition Intervention Trial cohort Gut 2009;58:636-42.
82. Watanabe Y, Kim HS, Castoro RJ és mtsai: Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes Gastroenterology 2009;136:2149-58.
83. Yu J, Cheng YY, Tao Q és mtsai: Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer Gastroenterology 2009;136:640-51.
84. Fareed KR, Kaye P, Soomro IN, és mtsai: Biomarkers of response to therapy in oesophago-gastric cancer Gut 2009;58:127-43.
85. Ikeda F, Doi Y, Yonemoto K és mtsai: Hyperglycaemia increases risk of gastric cancer posed by Helicobacter pylori infection: A population-based cohort study Gastroenterology 2009;136:1234-41.
86. Inoue M, Sasazukio S, Wakai K és mtsai: Green tea consumption and gastric cancer in Japanese: a pooled analysis of six cohort studies Gut 2009;58:1323-32.
87. Li C, Oh SJ, Kim S és mtsai: Risk factors of survival and surgical treatment for advanced gastric cancer with large tumor size. J Gastrointest Surg. 2009 May;13(5):881-5.
88. Qureshi AP, Ottensmeyer CA, Mahar AL és mtsai: Quality indicators for gastric cancer surgery: a survey of practicing pathologists in Ontario Ann Surg Oncol. 2009 Jul;16(7):1883-9. Epub 2009 May 7.
89. Sillah K, Griffiths EA, Pritchard SA és mtsai: Clinical impact of tumour involvement of the anastomotic doughnut in oesophagogastric cancer surgery. Ann R Coll Surg Engl. 2009 Apr;91(3):195-200.
90. Marrelli D, Pedrazzani C, Corso G és mtsai: Different pathological features and prognosis in gastric cancer patients coming from high-risk and low-risk areas of Italy. Ann Surg. 2009 Jul;250(1):43-50.
91. Marrelli D, Pedrazzani C, Corso G és mtsai: Different pathological features and prognosis in gastric cancer patients coming from high-risk and low-risk areas of Italy. Ann Surg. 2009 Jul;250(1):43-50.
92. Ozer I, Bostanci EB, Orug T és mtsai: Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer. Am J Surg. 2009 Jul;198(1):25-30.
93. Deng J, Liang H, Sun D, Pan Y: The Prognostic Analysis of Lymph Node-Positive Gastric Cancer Patients Following Curative Resection J Surg Res. 2009 Jan 10. [Epub ahead of print]
94. Yang SH, Zhang YC, Yang KH és mtsai: An evidence-based medicine review of lymphadenectomy extent for gastric cancer. Am J Surg. 2009 Feb;197(2):246-51. Epub 2008 Aug 22.
95. Schoenleber SJ, Schnelldorfer T, Wood CM és mtsai: Factors influencing lymph node recovery from the operative specimen after gastrectomy for gastric adenocarcinoma. J Gastrointest Surg. 2009 Jul;13 (7):1233-7.
96. Shin SH, Jung H, Choi SH és mtsai: Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. Ann Surg Oncol. 2009 May;16(5):1304-9.
A gyomor 135
97. Fukuda N, Sugiyama Y, Midorikawa A, Mushiake H: Prognostic significance of the metastatic lymph node ratio in gastric cancer patients World J Surg. 2009 Nov;33(11):2378-82.
98. Ichikura T, Sugasawa H, Sakamoto N és mtsai: Limited gastrectomy with dissection of sentinel node stations for early gastric cancer with negative sentinel node biopsy Ann Surg. 2009 Jun;249(6):942-7.
99. Song J, Oh SJ, Kang WH és mtsai: Robot-assisted gastrectomy with lymph node dissection for gastric cancer: lessons learned from an initial 100 consecutive procedures Ann Surg. 2009 Jun;249(6):927-32.
100. Song J, Oh SJ, Kang WH és mtsai: Robot-assisted gastrectomy with lymph node dissection for gastric cancer: lessons learned from an initial 100 consecutive procedures Ann Surg. 2009 Jun;249(6):927-32.
101. Schmidt C, Gerdes H, Hawkins W és mtsai: A prospective observational study examining quality of life in patients with malignant gastric outlet obstruction Am J Surg. 2009 Jul;198(1):92-9.
102. An JY, Ha TK, Noh JH, et al: Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM. Arch Surg. 2009 Jan;144(1):38-45; discussion 45.
103. Macdonald JS., J. Benedetti, S. Smalley, et. al: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 27:15s, 2009 (suppl; abstr 4515).
104. Kamei T, Kitayama J, Yamashita H, Nagawa H: Intraoperative blood loss is a critical risk factor for peritoneal recurrence after curative resection of advanced gastric cancer. World J Surg. 2009 Jun;33(6): 1240-6.
105. Njhawer M, Coit D, Brennan M et al: Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation. Am J Clin Oncol. 2009 Aug;32(4):356-62.
106. Ishido K, Azuma M, Koizumi W, et al: Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy., Pharmacogenet Genomics. 2009 Nov 5. [Epub ahead of print]
107. Nakamura J, Kitajima Y, Kai K et al: Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer. Oncol Rep. 2009 Oct;22(4): 693-9.
108. Yamada Y, S. Yamamoto, A. Ohtsu, et al: Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. J Clin Oncol 27:15s, 2009 (suppl; abstr 4535).
109. Schuhmacher C., P. Schlag, F. Lordick, et al: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol 27:15s, 2009 (suppl; abstr 4510).
110. Yoshikawa T, Sasako M, Yamamoto S, et al: Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009 Sep;96(9):1015-22.
111. Sym SJ, Chang HM, Ryu MH et-al: Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer. Ann Surg Oncol. 2009 Nov 26. [Epub ahead of print]
112. Yonemura Y, Endou Y, Shinbo M et al: Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol. 2009 Sep 15;100(4):311-6.
113. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart- Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009 Feb 20;27(6):851-6. Epub 2009 Jan 12.
136 Gastro Update 2010
114. Ha TK, Jung MS, Lee KH, et al: The Effect of Adjuvant Chemotherapy on Stage IV (T4N1-3M0 and T1-3N3M0) Gastric Cancer. Cancer Res Treat. 2009 Mar;41(1):19-23. Epub 2009 Mar 31.
115. Oba K: Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol. 2009 Apr;14(2):85-9. Epub 2009 Apr 24.
116. Sun P, Xiang JB, Chen ZY: Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009 Jan;96(1):26-33.
117. Strauss J, Hershman DL, Buono D, et al: Use of Adjuvant 5-Fluorouracil and Radiation Therapy After Gastric Cancer Resection Among the Elderly and Impact on Survival. Int J Radiat Oncol Biol Phys. 2009 Jun 17. [Epub ahead of print]
118. Fuse N., H. Fukuda, Y. Yamada et al: Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol 27:15s, 2009 (suppl; abstr 4514).
119. Ajani JA., W. Rodriquez, G. Bodoky, et al: Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. J Clin Oncol 27:15s, 2009 (suppl; abstr 4511).
120. Lee KH, Hyun MS, Kim HK, et al: Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer. Cancer Res Treat. 2009 Mar; 41(1):12-8. Epub 2009 Mar 31.
121. Tsuburaya A, H. Narahara, H. Imamura, et al: Updated result on the 2.5-year follow-up of GC0301/ TOP-002: Randomized phase III study of irinotecan plus S-1 (IRI-S) versus S-1 alone as first-line treatment for advanced gastric cancer (AGC). J Clin Oncol 27:15s, 2009 (suppl; abstr 4544).
122. Van Cutsem E., Y. Kang, H. Chung, et al: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27:18s, 2009 (suppl; abstr LBA4509).
123. Hyun Kim S, Lee GW, Il Go S, et al: A Phase II Study of Irinotecan, Continuous 5-Fluorouracil, and Leucovorin (FOLFIRI) Combination Chemotherapy for Patients With Recurrent or Metastatic Gastric Cancer Previously Treated With a Fluoropyrimidine-Based Regimen. Am J Clin Oncol. 2009 Dec 30. [Epub ahead of print]
124. Thuss-Patience PC., A. Kretzschmar, T. Deist et al: Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 27:15s, 2009 (suppl; abstr 4540).
102. Tabrizian P, Nguyen SQ, Divino CM: Laparoscopic management and longterm outcomes of gastrointestinal stromal tumors J Am Coll Surg. 2009 Jan;208(1):80-6.
103. Fiore M, Palassini E, Fumagalli E és mtsai: Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST) Eur J Surg Oncol. 2009 Jul;35(7):739-45.
104. Fukagawa T, Katai H, Saka M és mtsai: J Gastrointest Surg. 2009 May;13(5):886-9.
105. Firat O, Guler A, Sozbilen M és mtsai: Gastric remnant cancer: an old problem with novel concerns
Langenbecks Arch Surg. 2009 Jan;394(1):93-7.
106. Speicher JE, Thirlby RC, Burggraaf J és mtsai: Results of completion gastrectomies in 44 patients with postsurgical gastric atony J Gastrointest Surg. 2009 May;13(5):874-80.
107. Szarka LA, Camilleri M: Gastric emptying Clin Gastroenterol Hepatol 2009;7:823-7.
108. Jung HK, Choung RS, Locke III. GR: Th incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1966 to 2006 Gastroenterology 2009;136:1225-33.
A gyomor 137
109. Hyett B, Martinez FJ, Gill BM és mtsai: Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis Gastroenterology 2009;137:445-52.
110. Camilleri M: The stomach in diabetes: From Villain to Ally Clin Gastroenterol Hepatol 2009;7:285-7
111. ASGE Technology Committee: High-resolution and high-magnification endoscopes. Technology status
evaluation report. Gastrointest Endosc 2009;69:399-407.
112. ASGE Technology Committee: Confocal laser endomicroscopy. Gastrointest Endosc 2009;70:197-200.
113. Wallace MB, Fockens P: Probe-Based Confocal Laser Endomicroscopy. Gastroenterology 2009;136: 1509-25.
114. ASGE Technology Committee: Endocytoscopy. Gastrointest Edosc 2009;70:610-13.
115. Gill KRS, Pooley RA, Wallace MB: Magnetic resonance imaging compatibility of endoclips. Gastrint
Endosc 2009;70:532-36.
116. Cohen J. Optical Contrast Endoscopy: Is It Ready for Routine Use? Gastroenterology 2009;136:52-64.
117. Wolfsen HC: Endoscopic Ablation Therapy: Imaging and Advanced Technology in Action. Gastroenterology 2009;137:1225-37.
118. Curvers WL, van den Broek FJC, Reitsma JB, Dekker E, Bergman JGHM: Systematic review of narrow-band imaging for the detection and differentiation of abnormalities in the esophagus and stomach. Gastrointest Endosc 2009;69:307-17.
119. Yoshizawa M, Osawa H, Yamamoto H, Kita H, Nakano H, Satoh K és mtsai: Diagnosis of elevated-type early gastric cancers by the optimal band imaging system. Gastrointest Endosc 2009;69:19-28.
120. Sumiyama K, Tajiri H, Kato F, Imura T, Ono K, Ikeda K és mtsai: Pilot study for in vivo cellular imaging of the muscularis propria and ex vivo molecular imaging of myenteric neurons. Gastrointest Endosc 2009;69:1129-34.
121. Gotoda T, Oda I, Tamakawa K, Ueda H, Kobayashi T, Kakizoe T: Prospective clinical trial of magnetic- anchor-guided endoscopic submucosal dissection for large early gastric cancer. Gastrointest Endosc. 2009;69:10-15.
122. Wallace MB: Advances in Imaging and Technology of Pre-Invasive Neoplasia: The Big (and Small) Picture. Gastroenterology 2009;137: 1582-83.
123. Huang CS: The role of the endoscopist in a multidisciplinary obesity center. Gastrointest Endosc 2009;70:763-67.
124. Obstein KL, Thompson CC: Endoscopy after bariatric surgery. Gastrointest Endosc 2009;70:1161-66.
125. Tsesmeli N, Coumaros D: Review of endoscopic devices for weight reduction: old and new balloons
and implantable prostheses. Endoscopy 2009;41:1082-89.
126. Familiari P, Perri V, Iaconelli A, Leccessi L, Spada C, Marchese M és mtsai: Interim results of a feasibility study on endoscopic transoral vertical gastroplasty (TOGA) for obesity. Dig Liver Dis 2009;41:S38.
127. Buchwald H, Oien DM: Metabolic/bariatric surgery Worldwide 2008. Obes Surg. 2009 Dec;19(12): 1605-11.
128. Gu Q, Wu C, Gu L, Yu C, Fang Y, Cai S, Youming L: Comparison of the cardiovascular impacts of transnasal versus transoral gastroscopy in the aged patients with or without hypertension. Hepatogastroenterology 2009;56:1562-65.
129. Ha JF, Allanson E, Harsha Chandraratna H: Air embolism in gastroscopy. Int J Surg 2009;7:428-30.
130. Ristikankare M, Julkunen R, Heikkinen M, Laitinen T, Wang SX, Hartikainen J: Cardiac autonomic regulation during gastroscopy. Dig Liver Dis 2009;41: 648-52.
138 Gastro Update 2010
Onkológia 2009 elõtti hivatkozásai:
Ajani JA, Becker I, Pisters PW, et al: Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 2002;16(Suppl 5):16-8.
Ajani JA, Mansfield PF, Lynch PM, et al: Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999;17:2403-11.
Ajani JA, Mayer RJ, Ota DM, et al: Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993;85:1839-44.
Ajani JA, Ota DM, Jessup JM, et al: Resectable gastric carcinoma. An evaluation of preoperative and postopera- tive chemotherapy. Cancer 1991;68:1501-6.
Akoh JA, Macintyre IM: Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 970. Br J Surg 1992;79:293-9.
Alexander HR, Grem JL, Hamilton JM, et al: Thymidylate synthase protein expression. Cancer J Sci Am 1995;1:49.
Alexander HR, Kelsen D, Tepper JC: Cancer of the stomach. In: De Vita V, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. 5th edition Philadelphia: JB Lippincott; 1997. p. 1021-54.
Allum WH, Powell DJ, McConkey CC, Fielding JW: Gastric cancer: a 25-year review. Br J Surg 1989;76:535-40. AllumWH,HallisseyMT,Kelly KA. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet 1989;1:571-4.
Bajetta E, Buzzoni R, Mariani L, et al: Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002;13: 299-307.
Barber M, Fitzgerald RC, Caldas C: Familial gastric cancer-aetiology and pathogenesis. Best Pract Res Clin Gastroenterol 2006;20:721-34.
Bouche O, Raoul JL, Bonnetain F, et al: Randomized multicenter phase II trial of a biweekly regimen of fluo- rouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previ- ously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study- FFCD 9803. J Clin Oncol 2004;22:4319-28.
Bouche O, Ychou M, Burtin P, et al: Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005;16:1488-97.
Carrato A, Diaz-Rubio E, Medrano J, et al: Phase III trial of surgery versus adjuvant chemotherapy with mit- omycin C and tegafur plus uracil, starting within the first week after surgery, for gastric adenocarcinoma. Proc Am Soc Clin Oncol, J Clin Oncol 1995;14(Suppl):198.
Carriaga MT, Henson DE: The histologic grading of cancer. Cancer 1995;75:406-21.
Cascinu S, Labianca R, Alessandroni P, et al: Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997;15:3313-9.
Cascinu S, Labianca R, Barone C, et al: Adjuvant treatment of highrisk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007;99:601-7.
Cascinu S, Labianca R, Graziano F, et al: Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 1998;78:390-3.
Cascinu S, Scartozzi M, Labianca R, et al: High curative resection rate with weekly cisplatin, 5-fluorouracil,
A gyomor 139
epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 2004;90:1521-5.
Chipponi J, Huguier M, Pezet D, et al: Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 2004;187:440-5.
Cirera L, Balil A, Batiste-Alentorn E, et al: Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999;17:3810-5.
Cocconi G, Bella M, Zironi S, et al: Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1994;12:2687-93.
Cocconi G, Carlini P, Gamboni A, et al: Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 2003;14:1258-63.
Cocconi G, DeLisi V, Di Blasio B: Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 1982;66:1263-6.
Coggon D, Osmond C, Barker DJ: Stomach cancer and migration within England and Wales. Br J Cancer 1990;61:573-4.
Comis S: Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rep 1974;1:22-3.
Coombes RC, Schein PS, Chilvers CE, et al: A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 1990;8:1362-9.
Correa P, Chen VW: Gastric cancer. Cancer Surv 1994;19-20:55-76.
Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-7.
Cunningham D, Allum WH, Stenning SP, és mtsai: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20.
Cunningham D, Starling N, Rao S, és mtsai: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36-46.
Dank M, Zaluski J, Barone C, et al: Randomized phase III study comparing irinotecan combined with 5-fluo- rouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19:1450-7.
De Vita F, Giuliani F, Orditura M, et al: Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 2007;18:1354-8.
De Vita F, Orditura M, Matano E, et al: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX- 4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005;92:1644-9.
Dhillon PK, Farrow DC, Vaughan TL, et al: Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer 2001;93:148-52.
Di Costanzo F, Gasperoni S, Manzione L, et al: Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 2008;100:388-98.
140 Gastro Update 2010
Dinis-Ribeiro M,Yamaki G, Miki K, et al: Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004;11:141-7.
Douglass Jr HO, Lavin PT, Goudsmit A, Klaassen DJ, Paul AR: An Eastern Cooperative Oncology Group evalu- ation of combina tions of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984;2:1372-81.
Ducreux M, Nordlinger B, Ychou M, et al: Resected gastric adenocarcinoma: randomized trial of adjuvant chemotherapy with 5 FU-cisplatin (FUP). Final results of the FFCD 8801 trial. Proc Am Soc Clin Oncol, J Clin Oncol 2000;19(Suppl):241.
Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-64.
Engstrom PF, Lavin PT, Douglass Jr HO, Brunner KW: Postoperative adjuvant 5-fluorouracil plus methyl- CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 1985;55:1868-73.
Estape J, Grau JJ, Lcobendas F, et al: Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 1991;213:219-21.
Faivre J, Forman D, Esteve J, Gatta G: Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer 1998;34:2167-75.
Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2002 cancer incidence, mortality and prevalence world- wide. IARC cancerbase no. 5, version 2.0. Lyon: IARC Press; 2004.
Findlay M, Cunningham D, Norman A, et al: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609-16.
Glimelius B, Ekström K, Hoffman K, és mtsai: Randomized comparison between chemotherapy plus best sup- portive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8(2):163-8.
Gonzalez CA, Pera G, Agudo A, et al: Smoking and the risk of gastric cancer in the European prospective inves- tigation into cancer and nutrition (EPIC). Int J Cancer 2003;107:629-34.
Grau JJ, Estape J, Alcobendas F, et al: Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134.
Grau JJ, Estape J, Fuster J, et al: Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol 1998;16:1036-9.
Green FL, Page DL, Fleming ID, et al: AJCC cancer staging manual. 6th edition New York: Springer; 2002 Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbonadsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992;339:629-31.
Hallissey MT, Dunn JA, Ward LC, Allum WH: The second British Stomach Cancer Group trial of adjuvant radio- therapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994;343:1309-12.
Hamazoe R, Maeta M, Kaibara N: Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994;73:2048-52.
Hartgrink HH, Bonenkamp HJ, van de Velde CJ: Influence of surgery on outcomes in gastric cancer. Surg Oncol Clin N Am 2000;9: 91-117.
Helicobacter and Cancer Collaborative Group: Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
Hermans J, Bonenkamp HJ: In reply [letter]. J Clin Oncol 1994;12:879-80.
Hermans J, Bonenkamp JJ, Boon MC, et al: Adjuvant therapy after curative resection for gastric cancer: meta- analysis of randomized trials. J Clin Oncol 1993;11:1441-7.
A gyomor 141
Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ: Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer 1983;52:1105-12.
Hu JK, Chen ZX, Zhou ZG, et al: Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterol 2002;8:1023-8.
Huguier M, Destroyes JP, Baschet C, Le Henand F, Bernard PF: Gastric carcinoma treated by chemotherapy after resection: a controlled study. Am J Surg 1980;139:197-9.
Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002;9:278-86.
Imanaga H, Nakazato H: Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg 1977;2:213-21.
International Union Against Cancer: In: Sobin LH,Wittekind Ch, editors. TNM classification of malignant tumours. 6th ed. New York, Chichester, Weinheim, Brisbane, Singapore, Toronto: Wiley-Liss Book; 2002.
Irinoda T, Terashima M, Takagane A, et al: Carcinoembryonic antigen level in peritoneal washing is a prog- nostic factor in patients with gastric cancer. Oncol Rep 1998;5:661-6.
Janunger KG, Hafstrom L, Glimelius B: Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002;168:597-608.
Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47. Kampschoer GH, Maruyama K, SasakoM, Kinoshita T, van de Velde CJ: The effects of blood transfusion on the
prognosis of patients with gastric cancer. World J Surg 1989;13:637-43.
Kaneko S, Yoshimura T: Time trend analysis of gastric cancer incidence in Japan by histological types, 1975- 1989. Br J Cancer 2001;84:400-5.
Kang Y, Kang WK, Shin DB, et al: Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infu- sion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. Proc Am Soc Clin Oncol, J Clin Oncol 2006;24(Suppl):LBA4018.
Kang YK, ChoiDW, ImYH, et al: Aphase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Proc Am Soc Clin Oncol, J Clin Oncol 1996;15(Suppl):215.
Kelsen D, Karpeh M, Schwartz G, et al: Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of pre- operative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996;14:1818-28.
Klein HO, Wickramanayake PD, Dieterle F, et al: High-dose MTX/5- FU and adriamycin for gastric cancer. Semin Oncol 1983;10: 29-31.
Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-7.
Kramling HJ,Wilkowski R, Duhmke E, et al: Adjuvant intraoperative radiotherapy of stomach carcinoma. Langenbecks Arch Chir Suppl Kongressbd 1996;113:211-3.
Krook JE, O’Connell MJ, Wieand HS, et al: A prospective, randomized evaluation of intensive-course 5-fluo- rouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991;67:2454-8.
Leichman L, Silberman H, Leichman CG, et al: Preoperative systemic chemotherapy followed by adjuvant post- operative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 1992;10:1933-42.
Lenz HJ, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the
142 Gastro Update 2010
stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-82.
Lise M, Nitti D, Marchet A, et al: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995;13:2757-63.
Liu Y, Kaneko S, Sobue T: Trends in reported incidences of gastric cancer by tumour location, from 1975 to 1989 in Japan. Int J Epidemiol 2004;33:808-15.
Longmire Jr WP, Kuzma JW, Dixon WJ: The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric carcinoma. Ann Surg 1968;167:293-312.
Lordi ck F, Lorenzen S, Stollfuss J, et al: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 2005;93:190-4.
Louvet C, Andre T, Tigaud JM, et al: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-8.
Macdonald JS, Fleming TR, Peterson RF, et al: Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995;2:488-94.
Macdonald JS, Schein PS,Woolley PV, et al: 5-Fluorouracil, doxorubicin, and mitomycin (FAM)combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:533-6.
Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
Maehara Y, Kakeji Y, Oda S, et al: Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. Br J Cancer 2000;83:986-91.
Maehara Y, Kusumoto T, Takahashi I, et al: Predictive value of preoperative carcinoembryonic antigen levels for the prognosis of patients with well-differentiated gastric cancer. A multivariate analysis. Oncology 1994;51:234-7.
Mari E, Floriani I, Tinazzi A, és munkatársai: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol. 2000; 11(7):837-43.
Mari E, Floriani I, Tinazzi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000;11:837-43.
Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H: Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol 1996;23:360-8.
Micheli A, Mugno E, Krogh V, et al: Cancer prevalence in European registry areas. Ann Oncol 2002;13:840-65 Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006;9:245-53.
Nakajima T, Fukami A, Ohashi I, Kajitani T: Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm 1978;16:209-16.
Nakajima T, Nashimoto A, Kitamura M, et al: Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999;354:273-7.
Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T: Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 1984;2:1366-71. Neri B, de Leonardis V, Romano S, et al: Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer 1996;73:549-52.
A gyomor 143
Nitti D, Wils J, Dos Santos JG, et al: Randomized phase III trials of adjuvant FAMTXorFEMTXcompared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 2006;17:262-9.
Ochiai T, Sato H, Sato H, et al: Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients. Cancer Res 1983;43:3001-7.
Ott K, Sendler A, Becker K, et al: Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003;6:159-67.
Panzini I, Gianni L, Fattori PP, et al: Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002;88:21-7.
Parsonnet J: The incidence of helicobacter pylori infection. Aliment Pharmacol Ther 1995;9(Suppl 2):45-51.
Pinto C, Di FF, Siena S, et al: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18:510-7.
Plukker JT, Mulder NH, Sleijfer DT, Grond J, Verschueren RC: Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg 1991;78:955-8.
Pozzo C, Barone C, Szanto J, et al: Irinotecan in combination with 5- fluorouracil and folinic acid or with cis- platin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004;15:1773-81.
Preusser P,Wilke H, AchterrathW, et al: Phase II study with the combination etoposide, doxorubicin, and cis- platin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-7.
Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 1995;71:587-91.
Ries LA, Kosary CL, Hankey BF: SEER cancer statistics review 1973-1995. Bethesda: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1998.
Rohde H, Gebbensleben B, Bauer P, Stutzer H, Zieschang J: Has there been any improvement in the staging of gastric cancer? Findings from the German Gastric Cancer TNM Study Group. Cancer 1989;64:2465-81.
Rosen HR, Jatzko G, Repse S, et al: Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998;16:2733-8.
Roth AD, Maibach R, Martinelli G, et al: Docetaxel (Taxotere)- cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000;11:301-6.
Rougier P, Lasser P, Ducreux M, et al: Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 1994;5(Suppl 3):59-68.
Sakuramoto S, Sasako M, Yamaguchi T, és mtsai: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007, 357(18):1810-20. Erratum in: N Engl J Med. 2008; 358(18):1977.
Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R: Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994;12:970-4.
Schiessel R, Funovics J, Schick B, et al: Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: results of a randomized trial. Acta Med Austriaca 1989;16:68-9.
Schlag P, Schreml W, Gaus W, et al: Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results. Recent Results Cancer Res 1982;80:277-83.
144 Gastro Update 2010
Schuhmacher CH, Fink U, Bottcher K, et al: Neoadjuvant chemotherapy for locally advanced gastric cancer: a phase II study with etoposide, adriamycin and cisplatin. Ann Oncol 1994;5(Suppl 8):76a.
Serlin O, Wolkoff JS, Amadeo JM, Keehn RJ: Use of 5- fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 1969;24:223-8.
ShahMA, Ramanathan RK, Ilson DH, et al: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24(33):5201-6.
Sjodahl K, Lu Y, Nilsen TI, et al: Smoking and alcohol drinking in relation to risk of gastric cancer: a popula- tion-based, prospective cohort study. Int J Cancer 2007;120:128-32.
Takagane A, Terashima M, Abe K, et al: Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer 1999;2:122-8.
The Gastrointestinal Tumor Study Group: Controlled trial of adjuvant chemotherapy following curative resec- tion for gastric cancer. Cancer 1982;49:1116-22.
The Italian Gastrointestinal Tumor Study Group. Adjuvant treatments following curative resection for gastric cancer. Br J Surg 1988;75:1100-4.
Tsavaris N, Tentas K,Kosmidis P, et al: Arandomized trial comparing adjuvant fluorouracil, epirubicin, and mit- omycin with no treatment in operable gastric cancer. Chemotherapy 1996;42:220-6.
UICC (International Union Against Cancer). In: Sobin LH,Wittekind CH, editors: TNM classification of malig- nant tumours. 5th edition New York, Chichester, Weinheim, Brisbane, Singapore, Toronto: Wiley-Liss; 1997.
V. Boige, J. Pignon, B. Saint-Aubert, és mtsai: Final results of a randomized trial comparing preoperative 5-flu- orouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4510.
Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional flu- orouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.
Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W: Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003;39:1603-9.
Wagner AD, Grothe W, Haerting J, és mtsai: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18):2903-9.
Wagner AD, Grothe W, Haerting J, et al: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9.
Wagner AD, GrotheW, Haerting J, et al: Combination chemotherapies in advanced gastric cancer: An updated systematic review and metaanalysis. Proc Am Soc Clin Oncol, J Clin Oncol 2007;25(Suppl): 4555.
Wanebo HJ, Kennedy BJ, Chmiel J, et al: Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993;218:583-92.
WCRF & AICR: Food, nutrition, physical activity and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7. Wilke H, Preusser P, Fink U, et al: New developments in the treatment of gastric carcinoma. Semin Oncol 1990;17:61-70.
A gyomor 145
Wilke H, Preusser P, Fink U, et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989;7:1318-26.
Wils JA, Klein HO, Wagener DJ, et al: Sequential high-dose methotrexate and fluorouracil combined with dox- orubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9: 827-31.
Yamamura Y, Nishimura M, Sakamoto J, et al: A randomized controlled trial of surgical adjuvant therapy with mitomycin C, 5- fluorouracil and OK-432 in patients with gastric cancer. Gan To Kagaku Ryoho 1986;13:2134-40.
Yan TD, Black D, Sugarbaker PH, et al: A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for advanced gastric cancer. Proc Am Soc Clin Oncol, J Clin Oncol 2007;25(Suppl):4614.
Yonemura Y, Sawa T, Kinoshita K, et al: Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993;17:256-61.
YuW, Whang I, Suh I, et al: Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998;228:347-54.
Zhang ZX, Gu XZ, Yin WB, et al: Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys 1998;42:929-34.
